A clinical trial w a s conducted in C a m e r o o n in order to evaluate in humans the possible effect of a single dose of ivermectin (150 μg per kg) on the pre-adult stages of O n c h o c e r c a v o lv u lu s . The incidence of the skin microfilariae w a s measured in two groups of patients w h o initially had negative biopsies, and w h o were subsequently treated, immediately after the seasonal peak of transmission of O . v o lv u lu s , either with a combination of ivermectin + ferrous sulphate, or with ferrous sulphate alone. O n e year after the treatment, i.e. 14 months after the start of the transmission period, the proportion of patients with positive skin biopsies, and their m e a n microfilarial loads, did not differ significantly between the two groups. or more than 10 years onchocerciasis control has been based upon large-scale distribution of ivermectin. This drug has a direct and rapid effect on the microfilariae (mf) of O nchocerca volvulus, which are paralysed, and then drift passively along the lymphatic vessels up to the lymph nodes, where they are destroyed (Darge et a l . , 1991; Duke et a l , 1991; Vuong et al., 1992). Besides this, ivermectin has a more longer-term effect by suppressing, for several months, the production of mf by the adult female worms. The drug does not seem to affect the embryogenesis (Chavasse et al., 1992), but it causes the developed mf to accumulate in large numbers in the uteri, before dege nerating in situ (Awadzi et al., 1986). Although the effects of ivermectin on the mf and the adult stages of O. volvulus are well documented, rela tively little information is available on whether the drug has what is commonly called a "prophylactic" effect, a term which refers to a lethal or a moult-inhibiting 
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thérapeutique, prophylaxie, hommes, Cameroun. activity against the third or fourth stage larvae (L3s and L4s), or a lethal action on the immature adult worms. First studies, carried out in vitro, have demonstrated that ivermectin kills the L3s of O. lien alis and inhibits their moult from L3 to L4 (Court et al., 1985; Lok et a l . , 1987) . Following these results, Taylor et al. (1988) performed an in vivo study, whose objective was to evaluate the prophylactic effect of ivermectin against O. volvulus , and especially to compare the activity of the drug on the L3s and L4s of this species; eighteen chimpanzees were experimentally infected with L3s of O. volvulus, and then assigned to three groups: six ani mals were treated with a single dose of ivermectin (2 0 0 μg/kg) immediately after inoculation, six others received the same dose 28 days after inoculation, and six were left untreated; the results obtained suggested that "ivermectin may have a partial in vivo effect against the L3s of O. volvulus but has no effect against later larval stages". The first observations in humans were reported by Chavasse et al. (1992) , who com pared the proportion of immature adult O. volvulus found in nodules of patients treated either with pla cebo, or with five six-monthly doses of ivermectin; the authors did not find any difference, and concluded that ivermectin treatment did not prevent the development of L3s into adults. However, in another stage of the same trial, the proportion of young adult worms was found to be lower in a group of patients having received only a single dose of ivermectin, than in a similar group which had received five six-monthly treatments. The authors concluded that "the most likely explanation is that multiple doses of ivermectin have a partial chemoprophylactic effect reducing the deve lopment of infective larvae to young adults" (Kläger et al., 1993) . Since then, no further study was performed in humans, but the prophylactic effect of frequent doses of ivermectin on Onchocerca sp. was recently evaluated in Northern Cameroon, using an animal model: the development of O. ochengi nodules was compared in two groups of calves, both naturally exposed to the parasite, but one having been left untreated, and the other having received monthly doses of ivermectin for 21 months. At the end of the trial, none of the 15 treated calves had developed nodules, whereas five of the six untreated ones had done so; this demonstrated that ivermectin, when given every month, has a prophylactic effect against O. ochengi (Tchakouté et al., 1999) .
In this context of conflicting observations, we perfor med a controlled prospective trial aiming at evaluating, in the field, the effect of ivermectin on the pre-adult stages of O. volvulus, especially the L4s. For this pur pose, we compared the incidence of O. volvulus microfilaridermia in two groups of persons, who presented no skin mf at the outset of the trial but were then exposed naturally to transmission. One group was treated with a standard dose of ivermectin, and the other with a non-antiparasitic drug.
PATIENTS AND METHODS
Stu d y a r e a
The study area was chosen in accordance with two main criteria. The first was that the inten sity of transmission had to be high enough, so that the incidence of infection would be relatively important, and any eventual differences between the two groups would be perceptible within a relatively short time after treatment. The second was that the transmission had to show marked seasonal variation, so that a large proportion of the patients would be exposed during a limited period of time to a great number of L3s and would subsequently be harbouring a large number of the pre-adult stages of O. volvulus. In these circumstances, investigation of a prophylactic effect of ivermectin would be achieved by giving the drug at the peak of the transmission season or at a very short interval thereafter. The study was carried out in the Mbam Valley of the Cameroon Republic, where preliminary parasitological surveys had shown that the prevalence of onchocerciasis was very high in most of the villages (Boussinesq et al., 1992 al., 1998) . In order to get a sufficient number of patients with negative skin biopsies, we decided to perform the trial in Yambassa, which is a large village in the area, where most of the residents were farmers and thus exposed to the bites of infec tive Simulium vectors during their everyday activities.
S election o f patients
The period of the preliminary parasitological examina tions to identify persons eligible for the trial, and the date of treatment, were chosen taking into account the peak transmission period, and the presumed course of development of the parasite. It is known that the moult of L3 to L4 occurs three-five days after infestation (Bianco et al., 1989; Bain et al., 1998) and, following observations on O. lienalis, it was estimated that the moult of L4 to immature adults occurs 1.5-2.5 months later (Bianco & Müller, 1982) . However, a follow-up of antibody activities against various antigens in experimentally-infected monkeys suggested that the final moult from L4s to immature adults occurs 3 .5 to 5 months post-infection (Eberhard et al., 1991) . From a) this information, b) assuming that the course of development of the parasite in the monkeys might be a little delayed, when compared with that in the natural human host, and c) our knowledge of the peak trans mission period in the area (see above), we estimated that the maximum number of L4s present in the human population would be between February and June. We therefore decided to perform the pre-treatment para sitological examinations in March 1992, and to give the treatments in April, i.e. some 2.5 months after the beginning of the high transmission period, at a time when most of the L4s would have not moulted to the adult stage.
The parasitological examinations were done during the last week of March on 994 persons aged 5 years and above. A clinical examination was done to ensure that no palpable onchocercal nodules were present. Two standardized skin biopsies (one at each iliac crest) were then taken from each person using a 2 mm Holth-type comeo-scleral punch, and after 24 hours of incubation in saline, they were examined for emerged mf. A total of 149 persons presented neither nodules, nor mf in the skin, and were thus eligible for the trial. Those per sons who were found positive were treated with iver mectin (Mectizan®, 6 mg tablets), and then excluded from the trial.
Iverm e c tin an d pr o p h y l a x is o f h um an o n c h o c er c ia sis
T r e a t m e n t The 149 eligible persons were divided randomly into two groups, after stratification on the basis of sex and age. One group (control group) was to be treated with ferrous sulphate tablets (two generic tablets of 200 mg), and the other (named IVM group) with a combination of ferrous sulphate (two generic tablets of 200 mg) and ivermectin (Mectizan®, 6 mg tablets) at the standard dose of 150 μg/kg. The treatments were given in April, two weeks after the parasitological examinations, and taking into account the usual exclusion criteria for iver mectin treatment (pregnancy, poor state of health). Amongst the 149 eligible patients, five did not parti cipate in the treatment because of refusal or presence of an ivermectin exclusion criterion. In all, 73 persons received ivermectin plus ferrous sulphate, and 71 only ferrous sulphate. Eventual side-effects to treatment were followed-up during the two next days. M e a s u r e o f t h e in c id e n c e o f m ic r o f il a r id e r m ia a n d a n a l y sis
The date of post-treatment control was chosen taking into account information concerning the prepatent period for O. volvulus. The results of a follow-up of subjects negative for O. volvulus infection, who were exposed to one season of transmission, and then pro tected from subsequent infestations by anti-vectorial activities, have shown that a significant incidence of microfilaridermia occurs 7-12 months after the season of peak infectivity (Prost, 1980) . Studies conducted on experimentally-infected chimpanzees (Duke, 1980) , and on patients who had received effective macrofilaricidal treatment and were then naturally re-infected while living in an area of ongoing transmission (Duke, 1968) , suggested that the prepatent period ranges from 10 to 20 months. Based on these data, we decided to perform the re-examinations 14 months after the start of the high transmission period, i.e. in April 1993. All the participants in the trial were invited for this control, and the parasitological examinations were done using the same methods as during the pre-treatment survey. All the patients with positive skin biop sies were subsequently treated with ivermectin. The proportions of patients with positive skin biopsies at the control examination were compared using the x 2 test, and the distributions of the microfilarial counts were compared using the Wilcoxon-Mann-Whitney test.
RESULTS
T he level of endemicity in Yambassa was asses sed using the two indicators recommended by the World Health Organization: the age and sex standardized prevalence of skin mf (Moreau et al., 1978) , and the Community microfilarial load (Remme et al., 1986) . The values obtained for these two indi cators were 88.2 % and 37.9 mf per skin biopsy, res pectively, which confirmed that the intensity of trans mission in the village was suitable to lead to a high incidence of microfilaridermia. Amongst the 144 patients included in the trial, 126 accepted to participate in the April 1993 control exa minations, including 64 in the IVM group, and 62 in the control group (Table I) . The numbers of persons found to have positive skin biopsies at that time were 15 and 16, respectively (23.4 and 25.8 %), in the IVM and the control groups. The incidence rates in the two groups were not significantly different (P = 0.75). The geometric mean of the counts in the positive persons were 2.2 and 2.7 mf per biopsy, respectively, in the IVM and the control groups. The distribution of the Note de recherche counts did not differ significantly between the two groups (P = 0.57). Only four persons (two in each group) showed microfilarial loads above 10 mf per biopsy, and the highest one (22 mf per biopsy) was recorded in a patient belonging to the IVM group.
DISCUSSION
T he present trial was designed to evaluate whe ther ivermectin, when given at a single dose of 150 μg/kg just after the transmission period, could be effective as a prophylactic drug. Unfortuna tely, our results suggest either that it was not the case, or that, should this effect exist, it would not be per ceptible in practical conditions. Even so, our results are consistent with the parasitological and serological stu dies performed on chimpanzees treated with iver mectin either at the day of infection with O. volvulus (at a time when only L3s are present), or 28 days after (when probably only L4s are present), and which have led to the conclusion that the drug is effective on the L3s, and not on the L4s (Taylor et al., 1988; Chandrashekar et al., 1995) . Indeed, one cannot ignore the possibility that the mf observed in April 93 in the group treated with iver mectin could be the results of L3s transmitted either more than two-three months before the treatment (and maybe even during the previous high transmission season, one year before), or just after the dose. However, should the drug have been effective against the L4s, it seems to us that this would have led to a significant difference between the two groups, both in the proportion o f mf positive persons, and in the mean microfilarial loads. It is well known that ivermectin has a prophylactic acti vity against several species of filariae. In particular, it is active against both L3s and L4s of D irofilaria immitis and D ip etalon em a vitae, and the L3s of Litom osoides sigm odontis (Campbell, 1982) . The demonstration of an effect of ivermectin on the pre-adult stages of O. volvulus in humans would have had some impor tant consequences in terms of possible future appli cations of the drug. First, in those areas where the transmission of the parasite has been interrupted by anti-vectorial activities, an eventual recrudescence of transmission could be controlled by the implementa tion, within the weeks following its detection, of large scale ivermectin treatments of the populations exposed to re-infection. A second application of such an effect, would be the prophylactic treatment of persons coming temporarily into an area endemic for onchocerciasis. The results obtained on the cattle parasite O. och en g i (Tchakouté et al., 1999) suggest that monthly treat ments could also have a prophylactic effect against O. volvulus. However, such a regimen in humans might raise safety problems and would be difficult to put into effect on a large scale. Further studies should be conducted in other areas to confirm the present results obtained in Central Came roon and, owing to the conflicting results obtained with repeated six-monthly doses in Sierra Leone (Chavasse et al., 1992; Kläger et al., 1993) , it might be interesting to develop trials evaluating the possible prophylactic effect of three-or six-monthly regimens of ivermectin. However, one should keep in mind that, besides the very beneficial consequences which would be asso ciated with such a prophylactic effect, the latter might perhaps also have the major inconvenience of selec ting resistant parasites at an early stage of the deve lopmental cycle in man, before the multiplicative macrofilarial stage. Should the mechanisms of resis tance to ivermectin be similar in the pre-adult stages and the mf, this would have very negative conse quences.
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